Citi's Mark May says this is how Twitter can hit revenue forecasts next year.» Read More
Global markets are facing a "mismatch" with the future of U.S. monetary policy, according to St. Louis Federal Reserve President James Bullard.
Take a look at some of Monday's early movers:
Jim Cramer is preparing for next week and sees that one key datapoint from China will determine the direction of the market.
Chart analyst John Kosar, who correctly called the Nasdaq record rise a month ago, predicts where the U.S. dollar is headed next.
Stocks, stuck in their own zigzag pattern, remain vulnerable to the whims of unusually volatile currency markets in the week ahead.
Risky assets such as equities are not yet in bubble territory, Goldman Sachs Chief Global Equity Strategist Peter Oppenheimer said Monday.
UBS senior analyst Brent Thill says some hot tech names look good on the surface but could see slippery roads ahead.
The "Fast Money" traders give their final trades of the day.
These tips will help make you a savvy smartphone shopper -- and protect you from fraud.
Jim Cramer highlights why Nike is the model for success in dealing with currency issues.
Biotechs and small caps are the top performers on Wall Street, with the health-care subsector up about 8 percent for the week.
The strong dollar will impact earnings, the key is knowing what companies will weather the storm best, two experts said.
Jim Cramer takes a deep dive into this speculative pizza stock that's on fire.
Biotech hits a new record. A look at a disturbing biotech chart, with CNBC's Melissa Lee and the Options Action traders.
What has been the impact of the book?
Bonds, gold and oil go crazy. Can stocks stay calm? Volatility spreads beyond stocks, with CNBC's Melissa Lee and the Options Action traders.
How much more room does Facebook have to grow? CNBC's "Power Lunch" on Friday asked a bear and a bull for their takes.
Strategist Stacey Gilbert explains how to use a simple options strategy to play for further upside in small caps.
As the biotech sector and names such as Biogen continue to surge, finding value is becoming increasingly difficult, an expert says.
The best of #badhedgefundnames, which trended on Twitter Friday.